Engineering human cells to understand how genetic differences affect responses to toxins
Barcoded human cells engineered with heterozygous genetic diversity to uncover toxicodynamic variability
This study is looking to create a variety of human cell types that have been modified to see how different people react to harmful substances, helping us understand why some individuals may be more affected than others.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Amelia Technologies, LLC NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-10669812 on NIH RePORTER |
What this research studies
This research focuses on creating a diverse panel of human cells that have been genetically engineered to better understand how different individuals respond to toxic substances. By using a method called Barcoded Exon Tagging And Gene disruption, the researchers will develop human cell lines with specific genetic variations that can influence their reaction to genotoxic compounds. This approach aims to provide insights into the variability of responses seen in the human population, which is often overlooked in traditional toxicology studies that rely on animal models.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with diverse genetic backgrounds who may be affected differently by toxic substances.
Not a fit: Patients with conditions that do not involve genetic variability in response to toxins may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective safety assessments for drugs and chemicals based on individual genetic profiles.
How similar studies have performed: While this approach is innovative, similar research has shown that understanding genetic diversity can significantly enhance toxicological assessments.
Where this research is happening
Washington, United States
- Amelia Technologies, LLC — Washington, United States (Active)
Researchers
- Principal investigator: George, Jay — Amelia Technologies, LLC
- Study coordinator: George, Jay
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.